The FDA Thursday approved retifanlimab-dlwr (Zynyz; Incyte) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squaumous cell carcinoma of the anal canal, as well as a monotherapy for those with […]
Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer Read More »
Higher dietary inflammatory index (DII) scores are significantly associated with an increased risk of Alzheimer disease–related death among American adults, according to a study published in Experimental Gerontology.1 Although the exact mechanisms of Alzheimer disease remain unknown, accumulating evidence suggests
Anti-Inflammatory Diets May Help Reduce Risk of Alzheimer Disease–Related Death Read More »
Respiratory syncytial virus (RSV)–associated hospitalization rates were significantly lower among infants aged 0 to 7 months during the 2024-2025 RSV season, the first with widespread availability of prevention products, compared with pre–COVID-19 pandemic seasons, according to a recent study in
The real-world benefit of adding bevacizumab to a first-line chemotherapy regimen for patients with epithelial ovarian cancer was limited to those with high-risk prognostic factors, according to a study published Monday in Cancer.1 In the phase 3 GOG-0218 trial (NCT00262847),
On this episode of Managed Care Cast, The American Journal of Managed Care® speaks with Larragem Raines, MS, director of research at the Center for Innovation & Value Research, about her organization’s open-source value model for major depressive disorder (MDD).
Inside the Center’s MDD Value Model and Its Use of Dynamic Pricing Read More »
In the final interview clip with Raymond Osarogiagbon, MD, director of the multidisciplinary thoracic oncology program at Baptist Cancer Center, recorded at the American Association for Cancer Research Annual Meeting 2025, he highlights promising innovations designed to boost lung cancer
New Tools Aim to Close Lung Cancer Screening Gap: Raymond Osarogiagbon, MD Read More »
Compared with matched controls, all-cause health care resource use (HCRU) burden and costs are significantly higher in patients with uncomplicated urinary tract infections (uUTIs), according to a study published in BJGP Open.1 The researchers identified a lack of data on
Uncomplicated UTIs Tied to Greater Hospitalization Risk, Higher Health Care Costs Read More »
The FDA Thursday granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack; Verastem Oncology) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who received prior systemic therapy.1 This accelerated approval, granted well ahead
FDA Approves First Treatment for KRAS-Mutated Recurrent LGSOC Read More »
As confirmed measles cases continue to rise in the US, concerns are growing over declining vaccination rates. Measles cases surge in the US as vaccination rates decline, raising concerns about outbreaks and public health under Robert F. Kennedy Jr.’s leadership.
Measles Cases Surge Amid Declining Vaccination Rates Read More »
Arthritis was identified as a risk factor for prostate cancer by a recent study published in Investigative and Clinical Urology, offering new avenues for prevention and treatment strategies.1 Prostate cancer accounts for nearly 29% of all male adult malignancies, with
New Evidence Links Arthritis to Increased Prostate Cancer Risk Read More »
